Of note, administration of blocking antibodies against either CXCL5 or PD-L1 improved therapeutic efficacy, with the combination of CXCL5 and PD-L1 blocking antibodies demonstrating superior tumor control. The gene discussed is CD274; the disease is neoplasm.